Terumo Corp (TSE:4543)
円 2677.5 43 (1.63%) Market Cap: 3.91 Til Enterprise Value: 3.91 Til PE Ratio: 37.46 PB Ratio: 2.99 GF Score: 96/100

Q3 2022 Terumo Corp Earnings Call Transcript

Feb 09, 2022 / 08:00AM GMT
Release Date Price: 円2096 (+2.82%)
Naoki Muto
Terumo Corporation - Chief Accounting & Financial Officer and Executive Officer

I am the CFO, Muto. I will now explain the third quarter results for the fiscal year ending March 2022. First, the highlights from the quarter.

Q3 stand-alone revenue grew 8% from the previous year. Year-to-date revenue also grew 17%. The Cardiac and Vascular Company entered a COVID-19 recovery pattern, growing 12% from the previous year, with strong demand. Blood and Cell Technologies Company grew the next most.

Adjusted operating profits slowed slightly in the third quarter amid continued production adjustment to normalize inventory down from COVID safety stock levels as well as impact from higher freight and raw materials costs caused by global supply chain disruption.

Year-to-date profit grew 21% from the previous year. In light of these third quarter results, we will revise the annual guidance for revenue only upward by JPY 12 billion. Although we anticipate a temporary Q4 decrease in health care demand due to COVID omicron variant's impact, we decided to account for Q3

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot